Compare Amylx Pharmaceuticals Inc (AMLX) vs Altria Group Inc (MO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Altria Group Inc — how do they compare? Amylx Pharmaceuticals Inc trades at $17.77 (market cap $1.98B), while Altria Group Inc trades at $72.13 (market cap $119.88B). The key difference: Altria Group Inc is far larger — about 60.5× Amylx Pharmaceuticals Inc's market cap, and Altria Group Inc pays a 5.91% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | MO | |
|---|---|---|
Market Cap | $1.98B | $119.88B |
Sector | Health | Consumer Staples |
52-Week High | $18.70 | $74.55 |
52-Week Low | $7.64 | $54.72 |
Enterprise Value | $1.70B | $140.95B |
Dividend Yield | — | 5.91% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
Altria Group (MO) trades at $71.77, up 0.25% on the day, with a bullish technical signal and strong analyst support (16 buy ratings). The stock exhibits robust fundamentals, including a P/E of 14.99, net income margin of 39.52%, and consistent dividend payments, highlighted by a recent $1.06 dividend. Revenue remains stable around $20.1B, though net income dipped to $6.95B in 2025 from $11.3B in 2024. Positive cash flow of $1.33B in 2025 supports financial health, while technical indicators show support at $71 and resistance at $73.
Outlook: MO offers a compelling dividend yield and defensive appeal amid market volatility, but faces risks from declining smoking trends and regulatory pressures. Analyst consensus price target is $71.00, with potential upside to $79.00. Investors should weigh high debt levels and competitive threats against strong cash flow and brand loyalty for long-term income stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Altria Group Inc
Altria comprises Philip Morris USA, U.S. Smokeless Tobacco, John Middleton, Helix Innovations, and Philip Morris Capital, although the company plans to wind down Philip Morris Capital by the end of 2022. It holds a 10% interest in the world's largest brewer, Anheuser-Busch InBev. Through its tobacco subsidiaries, Altria holds the leading position in cigarettes and smokeless tobacco in the United States and the number-two spot in machine-made cigars. The company's Marlboro brand is the leading cigarette brand in the U.S. with a 43% share in 2020. Altria holds strategic investments in JUUL Labs (35% economic interest) and Cronos (42%).
Read more on MO →
